Quality of Life Assessment in Sarcoidosis

Clinics in Chest Medicine

Volumn 36, Issue 4, 2015, Pages 739-750

  Judson, Marc A ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Function; Health related quality of life; Patient reported outcomes; Sarcoidosis; Symptoms

Indexed keywords

CORTICOSTEROID;

BECK DEPRESSION INVENTORY; COMORBIDITY; CONCEPTUAL FRAMEWORK; CONSTRUCT VALIDITY; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; FATIGUE; FATIGUE ASSESSMENT SCALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; GRANULOMATOUS INFLAMMATION; HUMAN; KINGS SARCOIDOSIS QUESTIONNAIRE; LUNG SARCOIDOSIS; LUNG VOLUME; MENTAL DISEASE; OUTCOME ASSESSMENT; PAIN; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; SARCOIDOSIS; SARCOIDOSIS ASSESSMENT TOOL; SARCOIDOSIS HEALTH QUESTIONNAIRE; SHORT FORM 36; SPIROMETRY; STIGMA; SYMPTOMATOLOGY; WELLBEING; WHEEZING; HEALTH STATUS; PSYCHOLOGY;

HEALTH STATUS; HUMANS; QUALITY OF LIFE; SARCOIDOSIS; SURVEYS AND QUESTIONNAIRES;

EID: 84947868483     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2015.08.014     Document Type: Review

References (58)

1. Lynch J.P., Ma Y.L., Koss M.N., et al. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007, 28(1):53-74.
2. Judson M.A. The treatment of pulmonary sarcoidosis. Respir Med 2012, 106(10):1351-1361.
3. Judson M.A., Boan A.D., Lackland D.T. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 2012, 29(2):119-127.
4. Baydur A., Alsalek M., Louie S.G., et al. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001, 120(1):102-108.
5. Cox C.E., Donohue J.F., Brown C.D., et al. Health-related quality of life of persons with sarcoidosis. Chest 2004, 125(3):997-1004.
6. Cella D.F., Bonomi A.E. Measuring quality of life: 1995 update. Oncology (Williston Park) 1995, 9(Suppl 11):47-60.
7. Verghese A. Culture shock-patient as icon, icon as patient. N Engl J Med 2008, 359(26):2748-2751.
8. U.S.Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S.Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S.Department of Health and Human Services FDA Center for Devices and Radiological Health Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006, 4:79.
9. Patrick D.L., Burke L.B., Powers J.H., et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007, 10(Suppl 2):S125-S137.
10. Reynolds H.Y. Sarcoidosis: impact of other illnesses on the presentation and management of multi-organ disease. Lung 2002, 180(5):281-299.
11. Chang B., Steimel J., Moller D.R., et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001, 163(2):329-334.
12. Ligon C.B., Judson M.A. Impact of systemic corticosteroids on healthcare utilization in patients with sarcoidosis. Am J Med Sci 2011, 341(3):196-201.
13. Mahler D.A., Weinberg D.H., Wells C.K., et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85(6):751-758.
14. Norman G.R., Sridhar F.G., Guyatt G.H., et al. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care 2001, 39(10):1039-1047.
15. Judson M.A., Chaudhry H., Louis A., et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med 2015, 109(4):526-531.
16. Fayers P., Machin D. Quality of life: the assessment, analysis, and interpretation of patient-reported outcomes 2007, John Wiley and Sons, LTD, West Sussex (Untied Kingdom). 2nd edition.
17. Jones P.W., Quirk F.H., Baveystock C.M., et al. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. Am Rev Respir Dis 1992, 145(6):1321-1327.
18. Beaser R.S., Garbus S.B., Jacobson A.M. Diabetes mellitus. Quality of life and pharmacoeconomics in clinical trials 1996, 983-991. Lippincott-Raven, Philadelphia. 2nd edition. B. Spilker (Ed.).
19. Jaeschke R., Singer J., Guyatt G.H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989, 10(4):407-415.
20. Victorson D.E., Cella D., Judson M.A. Quality of life evaluation in sarcoidosis: current status and future directions. Curr Opin Pulm Med 2008, 14(5):470-477.
21. Cella D., Nowinski C.J. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 2002, 83(12 Suppl 2):S10-S17.
22. Ware J.E., Bjorner J.B., Kosinski M. Practical implications of item response theory and computerized adaptive testing: a brief summary of ongoing studies of widely used headache impact scales. Med Care 2000, 38(Suppl 9):II73-II82.
23. Cella D., Chang C.H. A discussion of item response theory and its applications in health status assessment. Med Care 2000, 38(Suppl 9):II66-II72.
24. Stansfeld S.A., Roberts R., Foot S.P. Assessing the validity of the SF-36 general health survey. Qual Life Res 1997, 6(3):217-224.
25. Basagana X., Barrera-Gomez J., Benet M., et al. A framework for multiple imputation in cluster analysis. Am J Epidemiol 2013, 177(7):718-725.
26. Hagell P., Hedin P.J., Meads D.M., et al. Effects of method of translation of patient-reported health outcome questionnaires: a randomized study of the translation of the Rheumatoid Arthritis Quality of Life (RAQoL) Instrument for Sweden. Value Health 2010, 13(4):424-430.
27. Eremenco S.L., Cella D., Arnold B.J. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof 2005, 28(2):212-232.
28. Judson M.A., Silvestri J., Hartung C., et al. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23(1):51-57.
29. Jastrzebski D., Ziora D., Lubecki M., et al. Fatigue in sarcoidosis and Exercise Tolerance, dyspnea, and quality of life. Adv Exp Med Biol 2015, 833:31-36.
30. Bourbonnais J.M., Malaisamy S., Dalal B.D., et al. Distance saturation product predicts health-related quality of life among sarcoidosis patients. Health Qual Life Outcomes 2012, 10:67.
31. Heij L., Niesters M., Swartjes M., et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012, 18:1430-1436.
32. Hoitsma E., De Vries J., van Santen-Hoeufft M., et al. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20(1):33-39.
33. Wirnsberger R.M., De Vries J., Jansen T.L., et al. Impairment of quality of life: rheumatoid arthritis versus sarcoidosis. Neth J Med 1999, 54(3):86-95.
34. Den Oudsten B.L., Zijlstra W.P., De Vries J. The minimal clinical important difference in the World Health Organization Quality of Life instrument-100. Support Care Cancer 2013, 21(5):1295-1301.
35. Marcellis R.G., Lenssen A.F., Elfferich M.D., et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011, 38(3):628-634.
36. Cox C.E., Donohue J.F., Brown C.D., et al. The Sarcoidosis health questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med 2003, 168(3):323-329.
37. Patel A.S., Siegert R.J., Creamer D., et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013, 68(1):57-65.
38. Judson M.A., Mack M., Beaumont J.L., et al. Differences for the sarcoidosis assessment tool. A new patient-reported outcome measure. Am J Respir Crit Care Med 2015, 191(7):786-795.
39. Victorson D.E., Cella D., Grund H., et al. A conceptual model of health-related quality of life in sarcoidosis. Qual Life Res 2013, 23(1):89-101.
40. Victorson D.E., Choi S., Judson M.A., et al. Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis. Qual Life Res 2014, 23(4):1301-1313.
41. Judson M.A., Highland K.B., Kwon S., et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28(2):139-145.
42. Baughman R.P., Judson M.A., Lower E.E., et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26(2):110-120.
43. Gvozdenovic B.S., Mihailovic-Vucinic V., Ilic-Dudvarski A., et al. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008, 102(11):1636-1642.
44. Baughman R.P., Sparkman B.K., Lower E.E. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007, 132(1):207-213.
45. Antoniou K.M., Tzanakis N., Tzouvelekis A., et al. Quality of life in patients with active sarcoidosis in Greece. Eur J Intern Med 2006, 17(6):421-426.
46. de Boer S., Kolbe J., Wilsher M.L. The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis. Respirology 2014, 19(7):1019-1024.
47. Michielsen H.J., Drent M., Peros-Golubicic T., et al. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006, 130(4):989-994.
48. De Vries J., Michielsen H., Van Heck G.L., et al. Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS). Br J Health Psychol 2004, 9(Pt 3):279-291.
49. Lower E.E., Harman S., Baughman R.P. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008, 133(5):1189-1195.
50. Drent M., Verbraecken J., van der Grinten C., et al. Fatigue associated with obstructive sleep apnea in a patient with sarcoidosis. Respiration 2000, 67(3):337-340.
51. Turner G.A., Lower E.E., Corser B.C., et al. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997, 14(1):61-64.
52. Wagner M.T., Marion S.D., Judson M.A. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005, 22(3):235.
53. De Vries J., Rothkrantz-Kos S., van Dieijen-Visser M.P., et al. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21(2):127-136.
54. Hinz A., Fleischer M., Brahler E., et al. Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 2011, 33(5):462-468.
55. de Kleijn W.P., Elfferich M.D., De Vries J., et al. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26(2):92-97.
56. de Kleijn W.P., De Vries J., Wijnen P.A., et al. Minimal (clinically) important differences for the fatigue assessment scale in sarcoidosis. Respir Med 2011, 105(9):1388-1395.
57. Kalkanis A., Yucel R.M., Judson M.A. The internal consistency of PRO fatigue instruments in sarcoidosis: superiority of the PFI over the FAS. Sarcoidosis Vasc Diffuse Lung Dis 2013, 30(1):60-64.
58. Cella D., Eton D.T., Lai J.S., et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002, 24(6):547-561.